LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2020

Conditions
Hodgkin DiseaseNon Hodgkin LymphomaLymphoepitheliomaLeiomyosarcoma
Interventions
BIOLOGICAL

LMP1/2 CTLs (ALCI - Group A)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"

BIOLOGICAL

LMP1/2 CTLs (ALCI - Group B)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"

BIOLOGICAL

LMP1/2 CTLs (ALCI - Group C)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"

BIOLOGICAL

LMP2 CTLs (ALSCER - Group A)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"

BIOLOGICAL

LMP2 CTLs (ALSCER - Group B)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"

BIOLOGICAL

LMP2 CTLs (ALSCER - Group C)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"

BIOLOGICAL

LMP1/2 CTLs (ALCI - Expansion - Group A)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2"

BIOLOGICAL

LMP1/2 CTLs (ALCI - Expansion Group B)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2"

BIOLOGICAL

LMP1/2 CTLs (ALCI - Expansion Group C)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2"

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00062868 - LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | Biotech Hunter | Biotech Hunter